Invivyd Reports Q4 2025 Financial Results and Clinical Trial Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy IVVD?
Source: Newsfilter
- Significant Revenue Growth: In Q4 2025, Invivyd achieved net product revenue of $17.2 million for PEMGARDA® (pemivibart), reflecting a 25% year-over-year increase and a 31% quarter-over-quarter rise, indicating strong market demand and execution in the antibody prophylaxis sector.
- Strong Cash Position: As of December 31, 2025, cash and cash equivalents stood at $226.7 million, bolstered by over $200 million raised in financing during the second half of 2025, ensuring funding for the DECLARATION clinical trial and potential commercialization efforts.
- Clinical Trial Progress: The DECLARATION Phase 3 clinical trial has achieved full enrollment, with FDA granting Fast Track designation for VYD2311, and top-line data expected in mid-2026, showcasing the company's proactive advancements in COVID-19 prevention.
- Management Changes: Distinguished scientist Michael Mina has been appointed Chief Medical Officer, expected to enhance the company's strategic execution in antibody research and market education, further elevating Invivyd's influence in the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IVVD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IVVD
Wall Street analysts forecast IVVD stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.890
Low
10.00
Averages
10.00
High
10.00
Current: 1.890
Low
10.00
Averages
10.00
High
10.00
About IVVD
Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Invivyd Q4 2025 Earnings Call Highlights
- New Chief Medical Officer: Invivyd announced the appointment of a new Chief Medical Officer, with Chairman Marc Elia emphasizing that this leadership change will bring fresh perspectives and strategic direction, which is expected to drive progress in clinical programs.
- PEMGARDA Revenue Growth: In Q4 2025, PEMGARDA net revenues grew by 31% over Q3 2025 and 25% year-over-year, totaling $53.4 million for the year, demonstrating strong market performance and ongoing commercial expansion for the company.
- Clinical Trial Progress: The DECLARATION study has reached target enrollment, with pivotal data expected in mid-2026, and management expresses optimism regarding clinical performance, indicating the company's competitiveness and market potential in the COVID-19 antibody space.
- Strong Cash Position: As of the end of 2025, Invivyd reported $226.7 million in cash and cash equivalents, ensuring sufficient funding for future clinical and commercial activities, supporting the expansion of its antibody platform and the development of new projects.
See More
Invivyd Reports Q4 2025 Financial Results and Clinical Trial Updates
- Significant Revenue Growth: In Q4 2025, Invivyd achieved net product revenue of $17.2 million for PEMGARDA® (pemivibart), reflecting a 25% year-over-year increase and a 31% quarter-over-quarter rise, indicating strong market demand and execution in the antibody prophylaxis sector.
- Strong Cash Position: As of December 31, 2025, cash and cash equivalents stood at $226.7 million, bolstered by over $200 million raised in financing during the second half of 2025, ensuring funding for the DECLARATION clinical trial and potential commercialization efforts.
- Clinical Trial Progress: The DECLARATION Phase 3 clinical trial has achieved full enrollment, with FDA granting Fast Track designation for VYD2311, and top-line data expected in mid-2026, showcasing the company's proactive advancements in COVID-19 prevention.
- Management Changes: Distinguished scientist Michael Mina has been appointed Chief Medical Officer, expected to enhance the company's strategic execution in antibody research and market education, further elevating Invivyd's influence in the biopharmaceutical industry.
See More
Invivyd Set to Announce FY Earnings with Significant Growth Expectations
- Earnings Announcement: Invivyd is set to release its FY earnings on March 5 before market open, with a consensus EPS estimate of -$0.10, reflecting a substantial year-over-year improvement of 93%, indicating a notable enhancement in financial performance.
- Strong Revenue Expectations: The company anticipates revenue of $51.72 million, representing a 103.8% year-over-year increase, which underscores the growing market demand and acceptance of its COVID-19 therapy products.
- Revision Trends: Over the past three months, EPS estimates have seen one upward revision with no downward adjustments, showcasing analysts' increasing confidence in the company's future performance, while revenue estimates have also experienced one upward revision, reinforcing market optimism about its growth potential.
- FDA Progress: Invivyd recently received FDA agreement on the late-stage trial design for its COVID-19 therapy and was granted fast track status, which will expedite its product launch process and enhance its competitive position in the market.
See More
Invivyd Aligns with FDA on LIBERTY Phase 3 Trial for VYD2311
- Stock Surge: Invivyd (IVVD) shares rose approximately 5% in premarket trading on Tuesday, reflecting positive market sentiment following the company's alignment with the FDA on the LIBERTY Phase 3 clinical trial, indicating increased investor confidence in its future prospects.
- Trial Design: The FDA has requested Invivyd to monitor myocarditis/pericarditis events associated with mRNA COVID-19 vaccines in the LIBERTY trial, a requirement that not only ensures trial safety but may also enhance market acceptance of VYD2311 as a potential preventative option for COVID-19.
- Trial Progress: Invivyd has initiated its registrational Phase 3 trial, DECLARATION, evaluating the efficacy of single or monthly dosing of VYD2311 in preventing symptomatic COVID-19, with topline data from 1,770 participants expected in mid-2026, which will provide crucial evidence for market launch.
- Market Outlook: The development of VYD2311 not only complements existing COVID-19 vaccines but may also offer a new preventative option for younger individuals, and as concerns about vaccine side effects grow, Invivyd's strategic position in the biopharmaceutical market is likely to strengthen.
See More
Invivyd Launches LIBERTY Clinical Trial for VYD2311
- LIBERTY Trial Launch: Invivyd has announced the initiation of the LIBERTY Phase 3 clinical trial, designed to evaluate the safety and immunological profile of VYD2311 compared to mRNA COVID vaccines, with an expected enrollment of 210 participants to explore both standalone and co-administration effects.
- FDA Feedback and Monitoring Requirements: The FDA provided constructive feedback on the LIBERTY trial design and requested specific monitoring for adverse events of special interest related to mRNA vaccines, particularly myocarditis/pericarditis, highlighting concerns for the young adult population to ensure trial safety.
- Background on DECLARATION Trial: The LIBERTY trial builds on the previous DECLARATION trial, which is expected to enroll 1,770 participants to assess the efficacy and safety of VYD2311 in preventing symptomatic COVID, further validating its clinical application potential.
- Antibody Candidate VYD2311: VYD2311 is a novel monoclonal antibody aimed at providing prophylactic and therapeutic options for COVID-19, with pharmacokinetic properties that may allow for effective antibody levels through intramuscular administration, catering to patient-friendly needs.
See More
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Invivyd Q4 2025 Earnings Call Highlights
- New Chief Medical Officer: Invivyd announced the appointment of a new Chief Medical Officer, with Chairman Marc Elia emphasizing that this leadership change will bring fresh perspectives and strategic direction, which is expected to drive progress in clinical programs.
- PEMGARDA Revenue Growth: In Q4 2025, PEMGARDA net revenues grew by 31% over Q3 2025 and 25% year-over-year, totaling $53.4 million for the year, demonstrating strong market performance and ongoing commercial expansion for the company.
- Clinical Trial Progress: The DECLARATION study has reached target enrollment, with pivotal data expected in mid-2026, and management expresses optimism regarding clinical performance, indicating the company's competitiveness and market potential in the COVID-19 antibody space.
- Strong Cash Position: As of the end of 2025, Invivyd reported $226.7 million in cash and cash equivalents, ensuring sufficient funding for future clinical and commercial activities, supporting the expansion of its antibody platform and the development of new projects.
See More
Invivyd Reports Q4 2025 Financial Results and Clinical Trial Updates
- Significant Revenue Growth: In Q4 2025, Invivyd achieved net product revenue of $17.2 million for PEMGARDA® (pemivibart), reflecting a 25% year-over-year increase and a 31% quarter-over-quarter rise, indicating strong market demand and execution in the antibody prophylaxis sector.
- Strong Cash Position: As of December 31, 2025, cash and cash equivalents stood at $226.7 million, bolstered by over $200 million raised in financing during the second half of 2025, ensuring funding for the DECLARATION clinical trial and potential commercialization efforts.
- Clinical Trial Progress: The DECLARATION Phase 3 clinical trial has achieved full enrollment, with FDA granting Fast Track designation for VYD2311, and top-line data expected in mid-2026, showcasing the company's proactive advancements in COVID-19 prevention.
- Management Changes: Distinguished scientist Michael Mina has been appointed Chief Medical Officer, expected to enhance the company's strategic execution in antibody research and market education, further elevating Invivyd's influence in the biopharmaceutical industry.
See More
Invivyd Set to Announce FY Earnings with Significant Growth Expectations
- Earnings Announcement: Invivyd is set to release its FY earnings on March 5 before market open, with a consensus EPS estimate of -$0.10, reflecting a substantial year-over-year improvement of 93%, indicating a notable enhancement in financial performance.
- Strong Revenue Expectations: The company anticipates revenue of $51.72 million, representing a 103.8% year-over-year increase, which underscores the growing market demand and acceptance of its COVID-19 therapy products.
- Revision Trends: Over the past three months, EPS estimates have seen one upward revision with no downward adjustments, showcasing analysts' increasing confidence in the company's future performance, while revenue estimates have also experienced one upward revision, reinforcing market optimism about its growth potential.
- FDA Progress: Invivyd recently received FDA agreement on the late-stage trial design for its COVID-19 therapy and was granted fast track status, which will expedite its product launch process and enhance its competitive position in the market.
See More
Invivyd Aligns with FDA on LIBERTY Phase 3 Trial for VYD2311
- Stock Surge: Invivyd (IVVD) shares rose approximately 5% in premarket trading on Tuesday, reflecting positive market sentiment following the company's alignment with the FDA on the LIBERTY Phase 3 clinical trial, indicating increased investor confidence in its future prospects.
- Trial Design: The FDA has requested Invivyd to monitor myocarditis/pericarditis events associated with mRNA COVID-19 vaccines in the LIBERTY trial, a requirement that not only ensures trial safety but may also enhance market acceptance of VYD2311 as a potential preventative option for COVID-19.
- Trial Progress: Invivyd has initiated its registrational Phase 3 trial, DECLARATION, evaluating the efficacy of single or monthly dosing of VYD2311 in preventing symptomatic COVID-19, with topline data from 1,770 participants expected in mid-2026, which will provide crucial evidence for market launch.
- Market Outlook: The development of VYD2311 not only complements existing COVID-19 vaccines but may also offer a new preventative option for younger individuals, and as concerns about vaccine side effects grow, Invivyd's strategic position in the biopharmaceutical market is likely to strengthen.
See More
Invivyd Launches LIBERTY Clinical Trial for VYD2311
- LIBERTY Trial Launch: Invivyd has announced the initiation of the LIBERTY Phase 3 clinical trial, designed to evaluate the safety and immunological profile of VYD2311 compared to mRNA COVID vaccines, with an expected enrollment of 210 participants to explore both standalone and co-administration effects.
- FDA Feedback and Monitoring Requirements: The FDA provided constructive feedback on the LIBERTY trial design and requested specific monitoring for adverse events of special interest related to mRNA vaccines, particularly myocarditis/pericarditis, highlighting concerns for the young adult population to ensure trial safety.
- Background on DECLARATION Trial: The LIBERTY trial builds on the previous DECLARATION trial, which is expected to enroll 1,770 participants to assess the efficacy and safety of VYD2311 in preventing symptomatic COVID, further validating its clinical application potential.
- Antibody Candidate VYD2311: VYD2311 is a novel monoclonal antibody aimed at providing prophylactic and therapeutic options for COVID-19, with pharmacokinetic properties that may allow for effective antibody levels through intramuscular administration, catering to patient-friendly needs.
See More
